Market Research Reports and Industry Reports

Gallbladder Cancer - Pipeline Review, H2 2017

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Gallbladder Cancer - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H2 2017, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.

Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history, gallstones, gender and choledochal cysts. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Gallbladder Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Gallbladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gallbladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 14, 4 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Gallbladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gallbladder Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Gallbladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gallbladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gallbladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gallbladder Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gallbladder Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gallbladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Gallbladder Cancer - Overview 7
Gallbladder Cancer - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 11
Products under Development by Companies 12
Products under Development by Universities/Institutes 14
Gallbladder Cancer - Therapeutics Assessment 15
Assessment by Target 15
Assessment by Mechanism of Action 18
Assessment by Route of Administration1
Assessment by Molecule Type3
Gallbladder Cancer - Companies Involved in Therapeutics Development5
4SC AG5
Advenchen Laboratories LLC5
Array BioPharma Inc5
Aslan Pharmaceuticals Pte Ltd6
Bayer AG6
BeiGene Ltd7
Eli Lilly and Co7
Halozyme Therapeutics Inc8
Hutchison MediPharma Ltd8
Ipsen SA9
Kringle Pharma Inc9
Leap Therapeutics Inc 30
MedImmune LLC 30
Molecular Templates Inc 30
Novartis AG 31
NuCana Plc 31
OncoTherapy Science Inc 32
VasGene Therapeutics Inc 32
Gallbladder Cancer - Drug Profiles 33
apatinib mesylate - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
BGBA-317 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
binimetinib - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
copanlisib hydrochloride - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
DKN-01 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
durvalumab - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
evofosfamide - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
HMPL-012 - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
irinotecan hydrochloride - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
merestinib - Drug Profile 116
Product Description 116
Mechanism Of Action 116
R&D Progress 116
NK-4 - Drug Profile 118
Product Description 118
Mechanism Of Action 118
R&D Progress 118
NUC-1031 - Drug Profile 120
Product Description 120
Mechanism Of Action 120
R&D Progress 120
OCVC-01 - Drug Profile 123
Product Description 123
Mechanism Of Action 123
R&D Progress 123
pazopanib hydrochloride - Drug Profile 124
Product Description 124
Mechanism Of Action 124
R&D Progress 124
PEGPH-20 - Drug Profile 133
Product Description 133
Mechanism Of Action 133
R&D Progress 133
ramucirumab - Drug Profile 143
Product Description 143
Mechanism Of Action 143
R&D Progress 143
resminostat - Drug Profile 155
Product Description 155
Mechanism Of Action 155
R&D Progress 155
trametinib dimethyl sulfoxide - Drug Profile 165
Product Description 165
Mechanism Of Action 165
R&D Progress 165
varlitinib - Drug Profile 170
Product Description 170
Mechanism Of Action 170
R&D Progress 170
Vas-01 - Drug Profile 175
Product Description 175
Mechanism Of Action 175
R&D Progress 175
Gallbladder Cancer - Dormant Projects 177
Appendix 178
Methodology 178
Coverage 178
Secondary Research 178
Primary Research 178
Expert Panel Validation 178
Contact Us 178
Disclaimer 179

List Of Tables

List of Tables
Number of Products under Development for Gallbladder Cancer, H2 2017 8
Number of Products under Development by Companies, H2 2017 10
Number of Products under Development by Universities/Institutes, H2 2017 11
Products under Development by Companies, H2 2017 12
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13
Products under Development by Universities/Institutes, H2 2017 14
Number of Products by Stage and Target, H2 2017 16
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 17
Number of Products by Stage and Mechanism of Action, H2 2017 19
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 20
Number of Products by Stage and Route of Administration, H2 2017 22
Number of Products by Stage and Molecule Type, H2 2017 24
Gallbladder Cancer - Pipeline by 4SC AG, H2 2017 25
Gallbladder Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017 25
Gallbladder Cancer - Pipeline by Array BioPharma Inc, H2 2017 26
Gallbladder Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017 26
Gallbladder Cancer - Pipeline by Bayer AG, H2 2017 27
Gallbladder Cancer - Pipeline by BeiGene Ltd, H2 2017 27
Gallbladder Cancer - Pipeline by Eli Lilly and Co, H2 2017 28
Gallbladder Cancer - Pipeline by Halozyme Therapeutics Inc, H2 2017 28
Gallbladder Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2017 29
Gallbladder Cancer - Pipeline by Ipsen SA, H2 2017 29
Gallbladder Cancer - Pipeline by Kringle Pharma Inc, H2 2017 29
Gallbladder Cancer - Pipeline by Leap Therapeutics Inc, H2 2017 30
Gallbladder Cancer - Pipeline by MedImmune LLC, H2 2017 30
Gallbladder Cancer - Pipeline by Molecular Templates Inc, H2 2017 31
Gallbladder Cancer - Pipeline by Novartis AG, H2 2017 31
Gallbladder Cancer - Pipeline by NuCana Plc, H2 2017 31
Gallbladder Cancer - Pipeline by OncoTherapy Science Inc, H2 2017 32
Gallbladder Cancer - Pipeline by VasGene Therapeutics Inc, H2 2017 32
Gallbladder Cancer - Dormant Projects, H2 2017 177

Gallbladder Cancer - Pipeline Review, H2 2017

Gallbladder Cancer - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H2 2017, provides an overview of the Gallbladder Cancer

USD 2000View Report

Gallbladder Cancer Global Clinical Trials Review, H2, 2017

Gallbladder Cancer Global Clinical Trials Review, H2, 2017GlobalDatas clinical trial report, Gallbladder Cancer Global Clinical Trials Review, H2, 2017 provides an overview of Gallbladder Cancer clinical trials scenario. This report

USD 2500View Report

EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026

EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in

USD 3995View Report

Bladder Cancer - Pipeline Review, H2 2017

Bladder Cancer - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Bladder Cancer - Pipeline Review, H2 2017, provides an overview of the Bladder Cancer

USD 2000View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Nov 2017
No. of Pages :179
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube